Last reviewed · How we verify
0.1% ropivacaine
At a glance
| Generic name | 0.1% ropivacaine |
|---|---|
| Also known as | Local Anesthetics |
| Sponsor | Fudan University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Does the Common Practice of Adding Diluted Epinephrine in Tranverse Abdominal Plan Block to Ropivacaine Significantly Decrease the Peak Systemic Resorption of Ropivacaine? (NA)
- Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty. (NA)
- Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery (NA)
- Superficial Parasternal Intercostal Plane Block in Cardiac Surgery Trial (NA)
- Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty (NA)
- Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients (PHASE4)
- Comparing PIEB and CEI for Labor Pain Relief (NA)
- Dexamethasone vs Dexmedetomidine vs Combination as Adjuvants to Popliteal Sciatic Nerve Block in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.1% ropivacaine CI brief — competitive landscape report
- 0.1% ropivacaine updates RSS · CI watch RSS
- Fudan University portfolio CI